Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 2, 2004, Pages 165-170

  Fonti, Rosa ^a,d   Del Vecchio, Silvana ^a   Zannetti, Antonella ^a   De Renzo, Amalia ^b   Catalano, Lucio ^b   Pace, Leonardo ^c   Rotoli, Bruno ^b   Salvatore, Marco ^c  

^a CNR   (Italy)

^b Dipartimento di Medicina Sperimentale   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NONE   (Italy)

Author keywords

99mTc MIBI; Multidrug resistance; Multiple myeloma; P glycoprotein; Washout

Indexed keywords

DIATRIZOATE; FICOLL; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C219; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOISOTOPE DISTRIBUTION; WHOLE BODY SCINTISCANNING;

BONE MARROW; DIAGNOSTIC IMAGING; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; P-GLYCOPROTEIN; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI;

EID: 2542469508     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804323071931     Document Type: Article

References (28)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature 2002;2:48.
2. 99mTc-MIBI scanning in multiple myeloma. Br J Cancer 1996;74:1815.
3. Sonneveld P, Lokhorst HM, Vossebeld P. Drug resistance in multiple myeloma. Semin Hematol 1997;34:34.
4. Adams BK, Fataar A, Nizami MA. Technetium-99m-sestamibi uptake in myeloma. J Nucl Med 1996;37:1001.
5. EI-Shirbiny AM, Yeung H, Imbriaco M, et al. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 1997;38:1208.
6. Pace L, Catalano L, Pinto AM, et al. Different patterns of technetium-99m-sestamibi uptake in multiple myeloma. Eur J Nucl Med 1998;25:714.
7. Catalano L, Pace L, Califano C, et al. Detection of focal myeloma lesions by technetium-99m-sestamibi scintigraphy. Haematologica 1999;84:119.
8. 99mTc-MIBI in patients with multiple myeloma. Eur J Nucl Med 2001;28:214.
9. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of Hexaxis (2-methoxyisobutyl isonitrile) Technetium (I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826.
10. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, et al. Uptake of the cation Hexaxis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198.
11. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of Hexaxis (2-methoxyisobutylisonitrile) Technetium (I) in cultured mouse fibroblasts. J Nucl Med 1990;31:1646.
12. Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977.
13. Piwnica-Worms D, Rao VV, Kronauge JF, et al. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochem 1995;34:12210.
14. Crankshaw CL, Marmion M, Luker GD, et al. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein. J Nucl Med 1998;39:77.
15. Del Vecchio S, Ciarmiello A, Pace L, et al. Washout of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997;38:1348.
16. 99mTc-sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24:150.
17. Kostakoglu L, Guc D, Canpinar H, et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 1998;39: 1191.
18. 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: Comparison with therapy response. Eur J Nucl Med 2001;28:1341.
19. Sun SS, Shiau YC, Lin CC, et al. Correlation between P-glycoprotein (Pgp) expression in parathyroid and Tc-99m-MIBI parathyroid image findings. Nucl Med Biol 2001;28:929.
20. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis. Eur J Nucl Med Mol Imaging 2002;29:876.
21. Fitzgerald MG, Hosking CS. Cell structure and percent viability by a slide centrifuge technique. J Clin Pathol 1982;35:191.
22. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. Histochem Cytochem 1981; 29:577.
23. Sonneveld P, Segeren CM. Changing concepts in multiple myeloma: From conventional chemotherapy to high-dose treatment. Eur J Cancer 2003;39:9.
24. Marie JP, Zhou DC, Gurbuxani S, et al. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 1996;32:1034.
25. Mongkonsritragoon W, Kimlinger T, Ahmann G, et al. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma, and amyloidosis? Leuk Lymphoma 1998;29:577.
26. Perez-Simon JA, Valverde B, Martinez A, et al. Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma. Cytometry 1999;38:24.
27. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 1999;6:53.
28. Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin, and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study. Br J Haematol 2001;115:895.